Skip to content

Case reports of severe dolutegravir-related depression

Few people with HIV starting raltegravir and dolutegravir change therapy because of side-effects

People treated with atazanavir had lower risk of stroke and heart attack

Researchers say rule out depression, anxiety, unemployment and other stresses before blaming cognitive impairment for everyday difficulties

Risk score can identify which HIV-positive people with controlled viral load are at greatest risk of neurocognitive decline

Switching from efavirenz to lopinavir/ritonavir has no meaningful impact on neurological function, says UK study

Studies look at brain and cognitive changes in people with HIV as they age

Dolutegravir and central nervous system side-effects: abacavir, older age increase the risk

Romina Quercia speaking at HIV Glasgow. Image credit: HIV Drug Therapy Glasgow 2016

Less than 100% adherence to HIV therapy, even with viral suppression, can lead to more inflammation and immune activation